FDA Grants Breakthrough Therapy Designation to Trodelvy for Small Cell Lung Cancer
FDA granted Breakthrough Therapy designation to Trodelvy for extensive-stage small cell lung cancer (ES-SCLC) post-platinum chemotherapy. Based on phase 2 TROPiCS-03 study, Trodelvy showed 41.9% overall response rate as second-line treatment. Gilead plans phase 3 trial. Trodelvy, an antibody-drug conjugate targeting TROP2, is also indicated for advanced breast cancers.
Highlighted Terms
Related News
FDA Grants Breakthrough Therapy Designation to Trodelvy for Small Cell Lung Cancer
FDA granted Breakthrough Therapy designation to Trodelvy for extensive-stage small cell lung cancer (ES-SCLC) post-platinum chemotherapy. Based on phase 2 TROPiCS-03 study, Trodelvy showed 41.9% overall response rate as second-line treatment. Gilead plans phase 3 trial. Trodelvy, an antibody-drug conjugate targeting TROP2, is also indicated for advanced breast cancers.